Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML

Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase III clinical trial of pracinostat and azacitidine combination to treat adults with newly diagnosed acute myeloid leukaemia (AML).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news